These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18366293)

  • 1. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
    Slovin SF
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):465-74. PubMed ID: 18366293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF
    Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic targeting: how to channel a minimal response for maximal outcome.
    Slovin SF
    Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccines for the treatment of prostate cancer.
    Alam S; McNeel DG
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of immunotherapy in the management of prostate cancer.
    Slovin SF
    Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
    Eymard JC; Gervais A; Jarcau R; Bernard J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine therapy for prostate cancer.
    Sonpavde G; Spencer DM; Slawin KM
    Urol Oncol; 2007; 25(6):451-9. PubMed ID: 18047951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
    Qi SY; Wang M; Xu Y
    Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E
    Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
    Lin AM; Hershberg RM; Small EJ
    Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.